Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105976
Status:
COMPLETED
Last Update Posted:
2008-07-11
First Post:
2005-03-18
Brief Title:
Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate MTX
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Double-Blind Parallel Placebo-Controlled Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels 25 75 and 20 mg of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical study is to see if an experimental drug called MM-093 is safe and effective in the treatment of rheumatoid arthritis MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein AFP Adults normally have very small amounts of AFP in their bloodstream However during pregnancy AFP levels in both the mother and the fetus are much higher than normal It has been observed that women with RA Rheumatoid Arthritis have fewer symptoms during pregnancy particularly during the third trimester At this time the levels of AFP in the blood of the mother and fetus are the highest This observation led researchers to begin examining AFP as a possible treatment for RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None